Medidata has followed up its successful IPO by inking a deal with Roche, which is reported to be pulling out of PhRMA and the ABPI, to provide the Swiss pharma with an enterprise-wide electronic EDC system.
Roche’s proposed $44bn acquisition of Genentech is facing some opposition with Wall Street saying the offer undervalues the company, disquiet among the biotech’s employees and shareholders suing the Swiss giant.
Roche has entered into an agreement to provide drug compounds for
cardiotoxicity testing using a cell-based platform that could play
a major role in the preclinical safety evaluation of drugs and
newly developed compounds.